Ocugen (OCGN) is a latecomer to the coronavirus stock party. But in true latecomer fashion, it has made a dazzling entrance. Shares are up year-to-date by 544%, as investors have cheered on the biotech firm’s endeavor to bring to the U.S. market another Covid-19 vaccine.

It’s a risky proposition, especially considering the rollout has been gathering pace, and there are now three authorized vaccines and another most likely on the way. Is there still room for one whose development is still some distance behind?

H.C. Wainwright’s Swayampakula Ramakanth seems to think so.

Ocugen has a deal with India-based Bharat Biotech to bring Bharat’s Covid-19 vaccine COVAXIN to the U.S. market. The agreement stipulates Ocugen will upon itself the jobs of U.S. clinical development, getting the

The post Is Ocugen Stock a Buy Right Now? This Is What You Need to Know – Yahoo Finance appeared first on RocketNews | Top News Stories From Around the Globe.